Matches in Wikidata for { <http://www.wikidata.org/entity/Q100788518> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q100788518 description "clinical trial" @default.
- Q100788518 description "ensayo clínico" @default.
- Q100788518 description "ensayu clínicu" @default.
- Q100788518 description "klinisch onderzoek" @default.
- Q100788518 description "клінічне випробування" @default.
- Q100788518 description "临床试验" @default.
- Q100788518 name "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19." @default.
- Q100788518 name "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19." @default.
- Q100788518 type Item @default.
- Q100788518 label "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19." @default.
- Q100788518 label "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19." @default.
- Q100788518 prefLabel "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19." @default.
- Q100788518 prefLabel "First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19." @default.
- Q100788518 P1132 Q100788518-96A731CB-5572-469C-B354-793B1DB6268F @default.
- Q100788518 P1476 Q100788518-8A6C4621-2576-4252-A169-CD7956C659BC @default.
- Q100788518 P17 Q100788518-29BBF828-6FC1-4513-9E28-F7E181DBB494 @default.
- Q100788518 P2899 Q100788518-279FC10A-E265-407F-A4C2-16147C02E6D0 @default.
- Q100788518 P3098 Q100788518-B050DEC2-08AD-4E4C-A3E8-8A9E2EBE8C9F @default.
- Q100788518 P31 Q100788518-52C405F0-DACB-4982-B600-E5972DA0840F @default.
- Q100788518 P4135 Q100788518-F5D4DA64-850F-4BA9-910E-C13AF80159BB @default.
- Q100788518 P580 Q100788518-4C9BBD41-BD75-4A7F-9BFC-A0BFDB17D21B @default.
- Q100788518 P582 Q100788518-421E6CC6-7A07-4D0A-A048-CBF4FDBAC01E @default.
- Q100788518 P6099 Q100788518-3F0D1BAC-2C47-461D-81D7-F1CDB7EF6171 @default.
- Q100788518 P6153 Q100788518-CBD9BFDC-F1B0-465E-B596-01AF6AEA28C0 @default.
- Q100788518 P6153 Q100788518-D47A3C77-7DE8-4D54-B690-0C687C9C9571 @default.
- Q100788518 P6153 Q100788518-EB65653E-46E3-42CB-A7B4-CEE9C7B76460 @default.
- Q100788518 P8005 Q100788518-3F2069AF-063B-4AE8-8AB3-C942CF52290E @default.
- Q100788518 P8363 Q100788518-88DEEF57-77F3-416C-B27B-5FFAA2365B58 @default.
- Q100788518 P859 Q100788518-1C59B142-0019-4994-A9D6-DC86F7008322 @default.
- Q100788518 P1132 "+56" @default.
- Q100788518 P1476 "A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND EXTENDED (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH MILD TO MODERATE COVID-19" @default.
- Q100788518 P17 Q30 @default.
- Q100788518 P2899 "+18" @default.
- Q100788518 P3098 "NCT04535167" @default.
- Q100788518 P31 Q30612 @default.
- Q100788518 P4135 "+75" @default.
- Q100788518 P580 "2020-09-09T00:00:00Z" @default.
- Q100788518 P582 "2021-03-21T00:00:00Z" @default.
- Q100788518 P6099 Q5452194 @default.
- Q100788518 P6153 Q30254145 @default.
- Q100788518 P6153 Q5874290 @default.
- Q100788518 P6153 Q7128506 @default.
- Q100788518 P8005 Q76649708 @default.
- Q100788518 P8363 Q78089383 @default.
- Q100788518 P859 Q206921 @default.